X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (48) 48
index medicus (40) 40
hematology (35) 35
oncology (33) 33
female (20) 20
male (20) 20
aged (18) 18
middle aged (17) 17
antineoplastic agents - therapeutic use (15) 15
cancer (14) 14
adult (13) 13
therapy (13) 13
hematology, oncology and palliative medicine (12) 12
imatinib (12) 12
leukemia (12) 12
treatment outcome (12) 12
article (10) 10
benzamides (10) 10
chronic myelogenous leukemia (10) 10
imatinib mesylate (10) 10
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (10) 10
protein kinase inhibitors - therapeutic use (10) 10
aged, 80 and over (9) 9
care and treatment (9) 9
pyrimidines - therapeutic use (9) 9
piperazines - therapeutic use (8) 8
antineoplastic agents - adverse effects (7) 7
bone-marrow-transplantation (7) 7
chronic myeloid leukemia (7) 7
dasatinib (7) 7
myelodysplastic syndromes (7) 7
myelofibrosis (7) 7
nilotinib (7) 7
quality of life (7) 7
chronic myeloid-leukemia (6) 6
discontinuation (6) 6
efficacy (6) 6
prognosis (6) 6
survival (6) 6
transplantation (6) 6
tyrosine (6) 6
young adult (6) 6
antineoplastic agents - administration & dosage (5) 5
chemotherapy (5) 5
drug therapy (5) 5
hemic and lymphatic diseases (5) 5
incidence (5) 5
international working group (5) 5
janus kinase 2 - antagonists & inhibitors (5) 5
medicine & public health (5) 5
mutation (5) 5
myelodysplastic syndromes - drug therapy (5) 5
pharmacology & pharmacy (5) 5
pyrimidines - adverse effects (5) 5
research (5) 5
retrospective studies (5) 5
trial (5) 5
abridged index medicus (4) 4
acute myeloid-leukemia (4) 4
age (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
clinical trials as topic (4) 4
disease-free survival (4) 4
geriatrics/gerontology (4) 4
jak2 inhibitor (4) 4
leukemia, myeloid, acute - drug therapy (4) 4
medicine, general & internal (4) 4
microstrip (4) 4
mortality (4) 4
outcomes (4) 4
piperazines - adverse effects (4) 4
polycythemia-vera (4) 4
pregnancy (4) 4
primary myelofibrosis - drug therapy (4) 4
protein kinase inhibitors - adverse effects (4) 4
risk (4) 4
safety (4) 4
time factors (4) 4
tyrosine kinase inhibitors (4) 4
adherence (3) 3
adolescent (3) 3
adults (3) 3
azacitidine - administration & dosage (3) 3
azacitidine - analogs & derivatives (3) 3
azacitidine - therapeutic use (3) 3
bandwidth (3) 3
broadband antennas (3) 3
clonal hematopoiesis (3) 3
dielectric resonator antennas (3) 3
dna methylation (3) 3
dna methylation - drug effects (3) 3
drug approval (3) 3
essential thrombocythemia (3) 3
follow-up (3) 3
follow-up studies (3) 3
health aspects (3) 3
hematopoietic stem cells (3) 3
internal medicine (3) 3
janus kinase 2 - genetics (3) 3
leukemia, myelogenous, chronic, bcr-abl positive - diagnosis (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 4, pp. 496 - 508
Journal Article
Journal Article
Clinical Lymphoma, Myeloma and Leukemia, ISSN 2152-2650, 08/2019, Volume 19, Issue 8, pp. 480 - 487
Clinical trials have shown that for some patients with chronic myeloid leukemia in chronic phase receiving tyrosine kinase inhibitors (TKIs), treatment-free... 
Adverse event | Trial | Withdrawal syndrome | Treatment-free remission | Quality of life | MAJOR MOLECULAR RESPONSE | DISCONTINUATION | RELAPSE | ONCOLOGY | IMATINIB | HEMATOLOGY | INTERIM ANALYSIS | FRONTLINE NILOTINIB | AGE
Journal Article
Journal Article
Current Hematologic Malignancy Reports, ISSN 1558-8211, 2/2019, Volume 14, Issue 1, pp. 56 - 61
Chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKI) have near-normal life expectancy. However, lifelong TKI therapy is... 
Chronic | Treatment | Discontinuation | Medicine & Public Health | Hematology | Geriatrics/Gerontology | Leukemia | Oncology | Myeloid | ONCOLOGY | IMATINIB | HEMATOLOGY | NILOTINIB | CHRONIC MYELOID-LEUKEMIA | Remission Induction - methods | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy | Tyrosine | Medical colleges
Journal Article
Case reports in hematology, ISSN 2090-6560, 2018, Volume 2018, pp. 6514604 - 6
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in Western countries. A common first-line therapy offered to qualifying patients... 
Encephalitis | Medical imaging | Nuclear magnetic resonance--NMR | Hematology | Leukemia | Meningitis | Lymphomas | Family medical history | Patients | Streptococcus infections
Journal Article
Journal Article
BMC Cancer, ISSN 1471-2407, 04/2018, Volume 18, Issue 1, pp. 359 - 8
Journal Article
Leukemia Research, ISSN 0145-2126, 11/2018, Volume 74, pp. 113 - 120
Journal Article
The Oncologist, ISSN 1083-7159, 09/2019, Volume 24, Issue 9, pp. 1253 - 1258
Background The standard treatment for chronic phase chronic myeloid leukemia (CML) is lifelong oral tyrosine kinase inhibitor (TKI) therapy. Multiple clinical... 
Polypharmacy | Myeloid | Goals | Decision making | Leukemia | Chronic phase | 5-YEAR | ONCOLOGY | IMATINIB | FOLLOW-UP | Hematologic Malignancies
Journal Article